EUCTR2017-000216-42-SE进行中（未招募）1 期
A multi-center, double-blind, placebo-controlled, Phase 4 study in patients with pulmonary arterial hypertension to assess the effect of selexipag on daily life physical activity and patient’s self-reported symptoms and their impacts - TRACE
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Male or female between 18 and 75 years old inclusive.
- •- Women of childbearing potential must have a negative serum
- •pregnancy test at planned visits and use an acceptable method of birth control from screening up to 30 days after study treatment
- •discontinuation.
- •- Symptomatic PAH belonging to one of the following subgroups only:
- •. Idiopathic
- •. Heritable
- •. Drug or toxin induced
- •. Associated with one of the following: connective tissue disease; HIV
- •infection; corrected simple congenital heart disease.
- •- With the following hemodynamic characteristics assessed by right
- •heart catheterization (RHC) prior to randomization:
- •. Mean pulmonary artery pressure (mPAP) = 25 mmHg
- •. Pulmonary vascular resistance (PVR) = 240 dyn•sec/cm5 (or 3 Wood Units)
- •. Pulmonary artery wedge pressure (PCWP) or left ventricular end-diastolic pressure (LVEDP) = 15 mmHg.
- •- Treatment with an endothelin receptor antagonist (ERA) for at least
- •90 days and on a stable dose for 30 days prior to randomization.
- •- Possible treatment with a Phosphodiesterase-5 inhibitor or sGC
- •stimulator must be ongoing for at least 90 days and on a stable dose for 30 days prior to randomization.
- •- WHO functional class (FC) II or III at randomization.
- •- 6-minute walk distance (6MWD) = 100 m at screening.
- •- Ability to walk without a walking aid.
- •- Valid baseline data for daily life physical activity (DLPA) and PAH-SYMPACT®.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •- Patients on a PAH-specific monotherapy targeting the nitric oxide
- •pathway (i.e. PDE-5 inhibitor or sGC stimulator).
- •- Patients treated with prostacyclin, prostacyclin analog or selexipag at any time prior to Day 1.
- •- Any hospitalization during the last 30 days prior to screening (Visit 1).
- •- Severe coronary heart disease or unstable angina.
- •- Documented severe hepatic impairment or severe renal insufficiency at screening (Visit 1).
- •- Participation in a cardio-pulmonary rehabilitation program based on
- •exercise training within 8 weeks prior to screening.
- •- Any factor or condition likely to affect full participation in the study or compliance with the protocol (such as adherence to protocol mandated procedures), as judged by the investigator.
研究者
相似试验
进行中（未招募）
不适用
Study to assess the safety and efficacy of KRP203 in active subacute cutaneous lupus erythematosus patients, who have shown poor response to standard treatment.Subacute cutaneous lupus erythematosus, in patients who do not respond to first line therapies (i.e. antimalrials)MedDRA version: 14.0Level: HLTClassification code 10025135Term: Lupus erythematosus (incl subtypes)System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-019689-10-GRovartis Services AG24
进行中（未招募）
1 期
Daily life physical activity and disease symptoms assessed in patients withpulmonary arterial hypertension (PAH) treated with selexipagMedDRA version: 21.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersPulmonary arterial hypertensionEUCTR2017-000216-42-PTActelion Pharmaceuticals Ltd100
进行中（未招募）
不适用
A multi-center, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy and tolerability of KRP203 in patients with active subacute cutaneous lupus erythematosus. - NDactive subacute cutaneous lupus erythematosusMedDRA version: 9.1Level: HLTClassification code 10025135EUCTR2010-019689-10-ITOVARTIS FARMA24
进行中（未招募）
不适用
A multi-center, double-blind, placebo-controlled, parallel-group study to establishproof-of-concept and explore the efficacy of different doses of ACT-129968 in adultpatients with partly controlled asthma. - CONTROAllergic asthmaMedDRA version: 12.1Level: LLTClassification code 10001705Term: Allergic asthmaEUCTR2009-011975-60-BGActelion Pharmaceuticals Ltd.412
进行中（未招募）
1 期
Daily life physical activity and disease symptoms assessed in patients withpulmonary arterial hypertension (PAH) treated with selexipagMedDRA version: 21.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersPulmonary arterial hypertensionEUCTR2017-000216-42-DEActelion Pharmaceuticals Ltd100